15 research outputs found
Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature
In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%.
However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors
currently used for risk stratification (advanced stage, high risk histology, and combined loss of
heterozygosity at 1p and 16q in chemotherapy-naĂŻve WTs) are present in only one third of these cases,
and the significance of these factors is prone to change with advancing knowledge and improved
treatment regimens. Therefore, we present a comprehensive, updated overview of the published
prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil
the importance of further investigating the significance of biological markers for WT recurrence in
international collaborations
The HST/ACS Coma Cluster Survey. II. Data Description and Source Catalogs
The Coma cluster was the target of a HST-ACS Treasury program designed for
deep imaging in the F475W and F814W passbands. Although our survey was
interrupted by the ACS instrument failure in 2007, the partially completed
survey still covers ~50% of the core high-density region in Coma. Observations
were performed for 25 fields that extend over a wide range of cluster-centric
radii (~1.75 Mpc) with a total coverage area of 274 arcmin^2. The majority of
the fields are located near the core region of Coma (19/25 pointings) with six
additional fields in the south-west region of the cluster. In this paper we
present reprocessed images and SExtractor source catalogs for our survey
fields, including a detailed description of the methodology used for object
detection and photometry, the subtraction of bright galaxies to measure faint
underlying objects, and the use of simulations to assess the photometric
accuracy and completeness of our catalogs. We also use simulations to perform
aperture corrections for the SExtractor Kron magnitudes based only on the
measured source flux and half-light radius. We have performed photometry for
~73,000 unique objects; one-half of our detections are brighter than the
10-sigma point-source detection limit at F814W=25.8 mag (AB). The slight
majority of objects (60%) are unresolved or only marginally resolved by ACS. We
estimate that Coma members are 5-10% of all source detections, which consist of
a large population of unresolved objects (primarily GCs but also UCDs) and a
wide variety of extended galaxies from a cD galaxy to dwarf LSB galaxies. The
red sequence of Coma member galaxies has a constant slope and dispersion across
9 magnitudes (-21<M_F814W<-13). The initial data release for the HST-ACS Coma
Treasury program was made available to the public in 2008 August. The images
and catalogs described in this study relate to our second data release.Comment: Accepted for publication in ApJS. A high-resolution version is
available at http://archdev.stsci.edu/pub/hlsp/coma/release2/PaperII.pd
Is Sustained Virological Response a Marker of Treatment Efficacy in Patients with Chronic Hepatitis C Viral Infection with No Response or Relapse to Previous Antiviral Intervention?
Background: Randomised clinical trials (RCTs) of antiviral interventions in patients with chronic hepatitis C virus (HCV) infection use sustained virological response (SVR) as the main outcome. There is sparse information on long-term mortality from RCTs. Methods: We created a decision tree model based on a Cochrane systematic review on interferon retreatment for patients who did not respond to initial therapy or who relapsed following SVR. Extrapolating data to 20 years, we modelled the outcome from three scenarios: (1) observed medium-term (5 year) annual mortality rates continue to the long term (20 years); (2) long-term annual mortality in retreatment responders falls to that of the general population while retreatment non-responders continue at the medium-term mortality; (3) long-term annual mortality in retreatment non-responders is the same as control group non-responders (i.e., the increased treatment-related medium mortality “wears off”). Results: The mean differences in life expectancy over 20 years with interferon versus control in the first, second, and third scenarios were -0.34 years (95% confidence interval (CI) -0.71 to 0.03), -0.23 years (95% CI -0.69 to 0.24), and -0.01 (95% CI -0.3 to 0.27), respectively. The life expectancy was always lower in the interferon group than in the control group in scenario 1. In scenario 3, the interferon group had a longer life expectancy than the control group only when more than 7% in the interferon group achieved SVR. Conclusions: SVR may be a good prognostic marker but does not seem to be a valid surrogate marker for assessing HCV treatment efficacy of interferon retreatment. The SVR threshold at which retreatment increases life expectancy may be different for different drugs depending upon the adverse event profile and treatment efficacy. This has to be determined for each drug by RCTs and appropriate modelling before SVR can be accepted as a surrogate marker
Compound Evolutionary History of the Rhesus Macaque Mhc Class I B Region Revealed by Microsatellite Analysis and Localization of Retroviral Sequences
In humans, the single polymorphic B locus of the major histocompatibility complex is linked to the microsatellite MIB. In rhesus macaques, however, haplotypes are characterized by the presence of unique combinations of multiple B genes, which may display different levels of polymorphism. The aim of the study was to shed light on the evolutionary history of this highly complex region. First, the robustness of the microsatellite MIB-linked to almost half of the B genes in rhesus macaques (Mamu-B)–for accurate B haplotyping was studied. Based on the physical map of an established haplotype comprising 7 MIB loci, each located next to a certain Mamu-B gene, two MIB loci, MIB1 and MIB6, were investigated in a panel of MHC homozygous monkeys. MIB1 revealed a complex genotyping pattern, whereas MIB6 analysis resulted in the detection of one or no amplicon. Both patterns are specific for a given B haplotype, show Mendelian segregation, and even allow a more precise haplotype definition than do traditional typing methods. Second, a search was performed for retroelements that may have played a role in duplication processes as observed in the macaque B region. This resulted in the description of two types of duplicons. One basic unit comprises an expressed Mamu-B gene, adjacent to an HERV16 copy closely linked to MIB. The second type of duplicon comprises a Mamu-B (pseudo)gene, linked to a truncated HERV16 structure lacking its MIB segment. Such truncation seems to coincide with the loss of B gene transcription. Subsequent to the duplication processes, recombination between MIB and Mamu-B loci appears to have occurred, resulting in a hyperplastic B region. Thus, analysis of MIB in addition to B loci allows deciphering of the compound evolutionary history of the class I B region in Old World monkeys
Demyelination and axonal damage in a non-human primate model of multiple sclerosis.
none9The demyelinating plaque is the paradigmatic lesion of multiple sclerosis (MS), but only recently attention has been given to axonal damage and to its role in the pathophysiology of disease. Albeit the possible relevance of axonal loss in MS and its experimental models, the amount and timing of axonal sufferance has been addressed only in experimental autoimmune encephalomyelitis (EAE) of rodents. In this report we observed that, in the marmoset model of EAE, axonal damage occurs early during the demyelinating process as assessed by immunoreactivity for amyloid precursor protein (APP) and non-phosphorylated neurofilaments (SMI-32 positive) detected mostly in early active lesions compared to late active and normal appearing white matter. The rare occurrence of morphological features of axonal transection, such as APP or SMI-32 positive spheroids and swellings, as well as an increase of neurofilament density in the demyelinated axons without accumulation of electron dense organelles or osmiophilic bodies, at electron microscopy, suggests that early axonal damage may be, at least in part, a reversible process. These findings are of relevance for the development of therapies, which can protect axons and enhance their function and survival.G. Mancardi;B. Hart;L. Roccatagliata;H. Brok;D. Giunti;R. Bontrop;L. Massacesi;E. Capello;A. UccelliMancardi, GIOVANNI LUIGI; B., Hart; Roccatagliata, Luca; H., Brok; Giunti, Debora; R., Bontrop; L., Massacesi; E., Capello; Uccelli, Antoni
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocols.
Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies